lung
transplant
recipi
ltr
lifelong
risk
infect
dissemin
diseas
owe
immunocompromis
state
besid
organ
failur
sepsi
infect
trigger
acut
chronic
graft
reject
increas
mortal
medic
prophylaxi
treatment
base
comprehens
diagnost
workup
includ
previou
histori
infect
airway
colonis
reduc
longterm
complic
mortal
common
bacteri
pathogen
includ
pseudomona
staphylococcu
whilst
aspergillu
cytomegaloviru
cmv
respect
commonest
fungal
viral
pathogen
clinic
symptom
variou
lung
transplant
recipi
present
asymptomat
sever
progress
regular
control
infect
paramet
daili
lung
function
test
lifelong
followup
specialist
transplant
centr
mandatori
earli
detect
bacteri
viral
fungal
infect
transplant
patient
receiv
intens
train
rule
conduct
concern
prevent
behaviour
recogn
earli
sign
post
transplant
complic
earli
detect
infect
complic
import
goal
reduc
major
complic
lung
transplant
due
chronic
immunocompromis
state
lung
transplant
recipi
ltr
increas
lifelong
risk
respiratori
tract
infect
sever
complic
tabl
immunosuppress
regim
includ
combin
calcineurin
inhibitor
cyclosporin
tacrolimu
antiprolif
agent
mycophenol
mofetil
mmf
azathioprin
sirolimu
prednison
impair
mucociliari
function
cough
reflex
alter
lymphat
drainag
donortransmit
pathogen
encourag
infect
besid
immunosuppress
state
clinic
cours
upper
lower
respiratori
tract
infect
vari
patient
may
present
system
symptom
fever
myalgia
fatigu
local
upper
lower
airway
symptom
without
deterior
lung
function
develop
symptom
necessit
urgent
evalu
transplant
centr
diagnost
workup
includ
patient
histori
physic
examin
laboratori
result
blood
ga
analysi
lung
function
test
chest
radiographi
conjunct
either
sputum
sampl
bronchoscopi
bronchoalveolar
lavag
bal
possibl
transbronchi
biopsi
initi
period
lung
transplant
ltx
infect
tend
bacteri
follow
fungal
microorgan
virus
immedi
appropri
treatment
essenti
prevent
complic
septicaemia
acut
respiratori
distress
syndrom
ard
acut
graft
reject
death
infect
acut
cellular
reject
ar
trigger
chronic
lung
allograft
dysfunct
clad
clad
emerg
umbrella
term
encompass
differ
form
chronic
graft
dysfunct
tradit
clad
consid
oblit
bronchiol
ob
character
fibroprolif
process
smaller
airway
along
peribronchi
perivascular
inflamm
lead
obstruct
ventilatori
defect
attempt
grade
graft
dysfunct
intern
societi
heart
lung
transplant
abbrevi
ard
acut
respiratori
distress
syndrom
ar
acut
cellular
reject
bal
bronchoalveolar
lavag
bcc
burkholderia
cepacia
complex
carv
communityacquir
respiratori
virus
cf
cystic
fibrosi
clad
chronic
lung
allograft
dysfunct
cmv
cytomegaloviru
ia
invas
aspergillosi
ishlt
intern
societi
heart
lung
transplant
ltr
lung
transplant
recipi
mmf
mycophenol
mofetil
nrad
neutrophil
revers
allograft
dysfunct
ob
oblit
bronchiol
pcr
polymeras
chain
reaction
ptld
posttranspl
lymphoprolif
disord
ra
restrict
allograft
syndrom
sotr
singl
organ
transplant
recipi
tmpsmx
trimethoprimsulfamethoxazol
ishlt
defin
term
bronchiol
obliteran
syndrom
bo
irrevers
declin
less
baselin
treatment
option
clad
remain
limit
unpredict
includ
immunomodul
oral
macrolid
azithromycin
clarithromycin
leukotrien
receptor
antagonist
montelukast
extracorpor
photopheresi
neutrophil
revers
allograft
dysfunct
nrad
repres
possibl
subset
within
clad
patient
initi
fulfil
bo
criteria
along
demonstr
profound
bal
neutrophilia
revers
complet
initi
azithromycin
contrast
anoth
recent
describ
clad
form
known
restrict
allograft
syndrom
ra
character
progress
restrict
ventilatori
defect
peripher
lung
fibrosi
form
gener
exhibit
rapid
treatment
refractori
cours
inevit
associ
high
mortal
develop
complic
affect
longterm
surviv
ltr
therefor
need
identifi
impair
cough
reflex
swallow
hypoventil
surgeri
may
increas
risk
pneumonia
common
pathogen
includ
pseudomona
aeruginosa
staphylococcu
aureu
well
gramneg
organ
import
resist
profil
manag
infect
requir
comprehens
workup
includ
microbiolog
cultur
molecular
test
detect
urinari
antigen
legionella
pneumococc
interim
broadspectrum
empir
antibiot
prophylaxi
result
avail
workup
includ
bronchoscopi
bronchoalveolar
lavag
bal
microscopi
cultur
polymeras
chain
reaction
pcr
test
indic
transbronchi
biopsi
preoper
airway
colon
gramneg
organ
eg
cystic
fibrosi
cf
patient
increas
pneumonia
risk
ltr
increasingli
refer
multiresist
gramneg
mrgn
organ
present
consider
challeng
treat
physician
decid
upon
appropri
antibiot
regim
mycobacteri
infect
ltr
rare
larg
due
nontubercul
mycobacteria
diagnosi
consid
especi
area
high
preval
pneumocysti
jirovecii
pneumonia
solid
organ
transplant
recipi
sotr
extrem
seriou
caus
signific
loss
graft
function
often
requir
intens
care
admiss
mortal
remain
around
despit
treatment
highdos
trimethoprimsulfamethoxazol
tmpsmx
suspect
pneumocystosi
urgent
workup
includ
bal
pcr
perform
treatment
start
immedi
given
high
risk
infect
among
sotr
lifelong
tmpsmx
p
jirovecii
prophylaxi
recommend
proven
effect
fig
mani
year
patient
burkholderia
cepacia
complex
bcc
consid
unsuit
transplant
candid
due
unaccept
high
risk
lethal
infect
transplant
improv
detect
identifi
differ
speci
vari
pathogen
subsequ
restrict
transplant
suitabl
reduc
includ
subtyp
includ
burkholderia
cenocepacia
genomovar
iii
burkholderia
gladioli
repres
main
mortal
risk
transplant
nocardia
spp
gramposit
aerob
actinobacteria
caus
lifethreaten
infect
predominantli
amongst
immunosuppress
patient
nocardia
asteroid
type
iv
nocardia
cyriacigeorgica
commonest
pathogen
lead
pulmonari
dissemin
extrapulmonari
nocardiosi
often
lethal
nocardiosi
may
present
varieti
radiolog
find
fig
make
differenti
pathogen
diseas
difficult
nocardia
spp
pneumonia
found
approxim
ltr
nocardia
farcinica
associ
poor
outcom
tissu
necrosi
occasion
associ
granulomat
respons
may
imit
histoplasmosi
tuberculosi
treatment
choic
protract
tmpsmz
secondlin
therapi
imipenem
amikacin
treatment
start
immedi
may
last
month
longer
pulmonari
system
nocardiosi
prevent
relaps
failur
treatment
aspergillu
speci
aspergillu
fumigatu
aspergillu
niger
aspergillu
flavu
aspergillu
versicolor
candida
speci
candida
albican
candida
glabrata
candida
krusei
repres
predomin
fungal
infect
identifi
bal
cytolog
evalu
serum
antigen
level
occasion
suspect
macroscop
endobronchi
lesion
observ
bronchoscopi
subsequ
confirm
microscop
assess
mucos
biopsi
fungal
infect
ltr
may
reflect
local
airway
involv
invas
form
involv
lung
parenchyma
dissemin
diseas
earli
infect
heal
bronchial
anastomosi
especi
common
aspergillu
endoscop
appear
resembl
ulcer
tracheobronch
necrosi
pseudomembran
format
airway
stenosi
sutur
line
dehisc
may
lead
subsequ
invas
neighbour
pulmonari
arteri
caus
sever
haemoptysi
understand
associ
high
mortal
case
invas
aspergillosi
ia
occur
within
first
year
transplant
affect
approxim
ltr
involv
lung
parenchyma
without
extrapulmonari
involv
typic
chest
xray
find
includ
pneumonia
dissemin
diseas
may
present
nodular
consolid
without
cavit
often
lack
characterist
appear
fig
risk
factor
ia
clad
hypogammaglobulinemia
previou
bronchial
stent
risk
stratif
patient
like
develop
invas
aspergillosi
colon
remain
difficult
colonis
usual
transient
increas
risk
invas
diseas
howev
associ
increas
mortal
ia
carri
still
high
mortal
galactomannan
test
might
help
diagnos
ia
serum
test
poor
sensit
rang
specif
detect
bal
fluid
show
sensit
specif
routin
screen
aspergillu
colon
time
transplant
posit
intraop
aspergillu
cultur
might
identifi
patient
higher
risk
ia
especi
patient
cfwhich
import
postop
followup
manag
candida
infect
report
first
month
transplant
risk
factor
candida
infect
includ
immunosuppress
state
heavi
use
broadspectrum
antibiot
frequent
need
renal
replac
therapi
protract
use
central
intraven
cathet
detect
base
cultur
histolog
bronchial
mucosa
biopsi
rather
bal
find
system
candida
infect
manifest
septicaemia
requir
urgent
treatment
fluconazol
gener
antifung
treatment
includ
echinocandin
caspofungin
micafungin
anidulafungin
azol
fluconazol
commonli
newer
azol
voriconazol
posaconazol
itraconazol
amphotericin
b
echinocandin
effect
candida
aspergillu
speci
natur
antifung
prophylaxi
vari
greatli
transplant
centr
term
treatment
choic
optim
durat
centr
reli
initi
azol
monotherapi
voriconazol
posaconazol
combin
inhal
amphotericin
b
follow
mainten
itraconazol
month
transplant
fluconazol
routin
use
prophylaxi
due
lack
anticandid
activ
nonalbican
speci
firstlin
therapi
ia
voriconazol
echinocandin
system
amphotericin
b
repres
secondlin
therapi
itraconazol
voriconazol
inhibitor
induc
lower
demand
calcineurin
inhibitor
dose
drug
level
concentr
azol
check
regularli
adjust
dose
serum
level
aim
optim
effect
limit
side
effect
like
visual
disturb
hepatotox
nephrotox
fungal
infect
caus
cryptococcu
zygomycet
histoplasmosi
scedosporium
ltr
rare
individu
manag
base
clinic
present
need
antifung
agent
resist
profil
consid
viral
infect
signific
impact
lung
transplant
common
pathogen
ltr
communityacquir
respiratori
virus
carv
includ
paramyxovirida
respiratori
syncyti
viru
b
rsv
parainfluenzaviru
human
metapneumoviru
hmpv
orthomyxovirida
influenza
b
picornavirida
rhinoviru
b
c
enteroviru
coronavirida
coronaviru
adenovirida
adenoviru
novel
parvoviru
human
bocaviru
hbv
data
viru
rare
season
variat
among
carv
predomin
influenza
rsv
winter
month
asymptomat
viral
carriag
rare
sometim
seen
picornaviru
coronaviru
infect
wherea
influenza
paramyxovirus
often
associ
high
symptom
load
lead
emerg
visit
hospitalis
high
rhinoviru
load
seem
associ
develop
clinic
symptom
ltr
gold
standard
earli
diagnosi
carv
nucleic
acid
amplif
test
naat
pcr
singl
multiplex
format
test
antibodi
immunofluoresc
assay
ifa
less
sensit
antivir
treatment
option
limit
paramyxovirus
treat
select
case
ribavirin
exist
data
oral
intraven
nebul
form
ribavirin
improv
outcom
sideeffect
consid
treatment
option
influenza
infect
includ
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
efficaci
data
use
ltx
recipi
limit
main
manag
goal
remain
prevent
adenoviru
infect
cidofovir
treatment
unexperienc
lack
data
ltr
cytomegaloviru
infect
affect
onethird
ltr
first
year
symptom
may
present
fever
pneumon
enter
nephriti
retin
hepat
myelosuppress
encephalopathi
cmv
risk
factor
ar
clad
posttranspl
lymphoprolif
disord
ptld
cmvnaiv
recipi
receiv
seroposit
cmvdonor
organ
possess
greater
risk
sever
infect
associ
increas
mortal
clinic
cours
cmvposit
recipi
pretranspl
known
less
distinct
compar
cmvneg
recipi
detect
cmv
peripher
blood
includ
quantit
pcr
semiquantit
antigenemia
test
tissueinvas
diseas
biopsi
may
proof
diagnosi
present
typic
inclus
bodi
standard
care
sever
cmv
infect
iv
ganciclovir
therapi
mgkg
week
follow
po
valganciclovir
week
consolid
persist
cmv
antigenemia
despit
treatment
drug
resist
ganciclovir
consid
altern
treatment
either
foscarnet
cidofovir
might
initi
centr
propos
cmv
prophylaxi
valganciclovir
mg
period
month
ltr
period
month
ltr
follow
transplant
drpatient
specif
antivir
cmv
prophylaxi
recommend
newer
agent
maribavir
leflunomid
letermovir
artesun
recent
propos
altern
agent
treatment
cmv
infect
resist
ganciclovir
cidofovir
foscarnet
immunosuppress
cytomegaloviru
epsteinebarr
viru
ebv
infect
associ
ptld
incid
report
ltr
ptld
manifest
highli
variabl
affect
organ
lead
nodal
extranod
involv
type
ptld
polymorph
monomorph
treatment
option
rituximab
tumor
vaccin
routin
perform
patient
one
year
posttransplant
current
data
show
around
one
third
immunosuppress
patient
achiev
protect
antibodi
respons
flu
vaccin
vaccin
inject
singl
intramuscular
dose
inactiv
vaccin
intraderm
booster
dose
significantli
improv
vaccin
immunogen
ltr
therefor
indic
gener
influenza
vaccin
ltr
well
toler
show
littl
advers
event
predominantli
local
effect
vaccin
rsv
cmv
vaccin
high
interest
still
develop
ongo
clinic
trial
respiratori
infect
ltr
challeng
problem
affect
graft
patient
surviv
patientbas
surveil
import
individu
medic
treatment
regard
prophylaxi
therapeut
regim
followup
monitor
recognit
former
infect
resist
profil
laboratori
find
eg
druginduc
neutropenia
acut
symptom
need
evalu
diagnost
workup
includ
lung
function
test
blood
test
chest
xray
ct
scan
surveil
bronchoscopi
bal
biopsi
pcr
ifa
earli
accur
detect
pathogen
crucial
prompt
effect
treatment
prevent
ltr
complic
reduc
mortal
